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A simple accurate and sensitive high-performance liquid chromatographic method for the determination of meloxicam and
piroxicam concentrations in small volume plasma samples has been developed. Following a liquid extraction using chloroform,
samples were separated by reversed-phase high-performance liquid chromatography on an XBridge C
18
column (4.6× 250mm)
and quantified using ultraviolet detection at 360 nm.The mobile phase was a mixture of water with glacial acetic acid (pH 3.0) and
acetonitrile (50 : 50), with a flow rate of 1.0mL/min. The standard curve ranged from 5 to 10,000 ng/mL for meloxicam in bearded
dragon (Pogona vitticeps) plasma and piroxicam in crane (Grus rubicunda) plasma. Intra- and interassay variability for meloxicam
and piroxicam were less than 10% and the average recovery was greater than 90% for both drugs. This method was developed in
bearded dragon and crane plasma and should be applicable to any species, making it useful for those investigators dealing with
small sample volumes, particularly when conducting pharmacokinetics studies which require multiple sampling from the same
animal.
1. Introduction
Meloxicam, 4-hydroxy-2-methyl-N-(5-methyl-1,3-thiazol-2-
yl)-1,1-dioxo-1𝜆6,2-benzothiazine-3-carboxamide, and pirox-
icam, 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-yl-1𝜆6, 2-
benzothiazine-3-carboxamide, are nonsteroidal anti-in-
flammatory drugs (NSAIDs) with analgesic properties. They
are generally used to treat osteoarthritis and rheumatoid
arthritis; however, they can be used for other painful condi-
tions such as injuries, cancer surgery, and dental infections.
Meloxicam preferentially inhibits the cyclooxygenase-2
(COX-2) enzyme over COX-1. The ability to only inhibit the
inflammatory COX proved to be revolutionary for pain man-
agement. The introduction of COX-2 preferential NSAIDs
has reduced stomach and intestinal side effects. While
piroxicam is used to treat painful conditions, it has recently
been used in a variety of protocols to treat squamous cell
carcinoma and hemangiosarcoma. Meloxicam can be metab-
olized to as many as four biologically inactive metabolites
depending on the species; however, the 5-hydroxy methyl
derivative is themost commonmetabolite. Piroxicammetab-
olism occurs via a cytochrome P450 2C isoform to multiple
biologically inactive metabolites, with 5-hydroxy-prioxicam
being the most common.
Nonsteroidal anti-inflammatory drugs are commonly
used in large and small veterinary practices for relief of
pain, fever, and inflammation. Increasing public awareness
of animal welfare will likely continue to make proper use of
NSAIDs a priority in the treatment of all domestic animals
for painful inflammatory conditions.Therefore knowledge of
the pharmacokinetics of NSAIDs in the specific species of
interest will be required to provide for the safe and efficacious
use of these drugs.
Meloxicam and piroxicam levels have been determined
using a number of analytical methods [1–19]. Although mass
spectrometry [1, 2, 10, 14] can produce the highest detection
sensitivity, it may not be readily available in all laboratories
and is expensive. The most economical method is high-
performance liquid chromatography with ultraviolet detec-
tion (HPLC-UV). In order to obtain a suitable limit of
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quantification (LOQ) for the determination of meloxicam
and piroxicam in biological samples several different pro-
cesses have been used. Some of the methods employed
include liquid-liquid extractions using diethyl ether [3, 5, 7,
12, 16] or methylene chloride [18, 19], protein precipitation
[4, 6, 13, 17], precolumn enrichment [8, 9, 15], and solid
phase extraction [11]. In many of the liquid-liquid extraction
methods developed, large amounts of organic solvents are
needed. Also, sample volumes for all the extraction methods
can be large, many requiring from 0.2 to 1mL of sample. Pre-
column enrichment can require the expense of precolumns
and the need for column switching. The aim of this paper
is to describe a simple, sensitive, and accurate method for
extracting meloxicam and piroxicam from small volume
plasma samples using HPLC.
2. Material and Methods
2.1. Instrumentation. The chromatography system consisted
of a 2695 separation module and a 2487 ultraviolet detector
(Waters, Milford, MA). Separation was achieved on a Waters
XBridge C
18
column (4.6 × 250mm, 5 𝜇m) preceded by
a 5 𝜇m XBridge C
18
guard column (3.9 × 20mm). The
mobile phase was an isocratic mixture of A: 990mL water
with 10mL 85% glacial acetic acid, pH 3.0 with 1N sodium
hydroxide, and B: acetonitrile (50 : 50). All solutions were
filtered through a 0.22𝜇mfilter and degassed before their use.
The water was replaced on a daily basis. The flow rate was
1.0mL/min, and the column and autosampler temperature
were ambient which was 23∘C. The ultraviolet detector was
set at a wavelength of 360 nm.
2.2. Reagents. Meloxicam (Figure 1)was purchased fromTor-
onto Research Chemicals (Ontario, Canada) and was 99%
pure. Piroxicam (Figure 1), which was the internal stan-
dard (99% purity), was purchased from US Pharmacopeia
(Rockville, MD). All reagent grade chemicals and solvents
were purchased from Fisher Scientific (Pittsburg, PA). Water
(18.2 megaohms) was obtained from a Barnstead Nanopure
Infinity (Dubuque, IA) ultrapure water system.
2.3. Preparation of Calibration Standards. Five milligrams
each of meloxicam or piroxicam was weighed using a Sarto-
rius Microbalance (Elk Grove, IL) and dissolved in methanol
to produce stock concentrations of 100 𝜇g/mL. Dilutions of
the meloxicam and piroxicam stock standards were prepared
in methanol to produce 0.1, 1, 5, and 10 𝜇g/mL working stock
solutions. Standards were aliquoted into 2mL vials to prevent
evaporation and cross contamination. All solutions were
protected from light in bottles wrapped in aluminum foil and
stored at −20∘C. By comparing standard areas over time it
was determined that solutions were stable for a minimum of
6 months.
For preparation of calibration standards and quality
control samples, appropriate volumes of stock solutions were
placed in screw top tubes and evaporated with nitrogen gas
and then untreated plasma was added. The final concentra-
tions for the calibration standard curve were 5, 10, 25, 50, 100,
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Figure 1: Structures of meloxicam and piroxicam.
250, 500, 800, 1000, 2500, 5000, and 10,000 ng/mL with qual-
ity control standards of 15, 750, 1250, 3000, and 7500 ng/mL.
Calibration standards and control samples were treated the
same as test samples. The calibration curve was constructed
by using the ratio of the peak area of the analyte divided by
the peak area of the internal standard versus the concentra-
tion. Linearity was assessed by unweighted linear regression
analysis. The calibration curve had a correlation coefficient
of 0.99 or better. The acceptance criterion for each back-
calculated standard and quality control concentration was
15% deviation from the nominal value except for lower limit
of quantification (LLOQ), which was set at 20%.
2.4. Sample Extraction. Meloxicam or piroxicamwas extract-
ed from bearded dragon (Pogona vitticeps), sandhill crane
(Grus canadensis), or sow plasma and sowmilk using a liquid
extraction. Previously frozen plasma or milk samples were
thawed, and 100 𝜇L was placed into a 7mL screw cap tube.
Fifteen microliters of piroxicam for meloxicam extraction or
meloxicam for piroxicam extraction (5𝜇g/mL) was added.
After the addition of 100 𝜇L of 1M hydrochloride and 2mL of
chloroform, tubes were vortex-mixed at a high speed for 60
seconds followed by centrifugation for 20minutes at 1000×g.
The supernatant was removed and placed in a clean 16 ×
100 glass test tube and then evaporated with nitrogen. After
evaporation, sampleswere redissolved in 250𝜇Lof themobile
phase and vortex-mixed and the supernatant was placed in
total recovery chromatographic vials (Waters, Milford, MA)
and then 100 𝜇L injected into the system.
3. Results and Discussion
3.1. Method Development and Optimization. The goal of
the study was to develop a simple method that did not
require the use of mass spectrometry, column switching, or
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large amounts of organic solvents. We found that ultraviolet
detection at 360 nm produced chromatograms with the
largest meloxicam and piroxicam areas compared to those
at 350 nm, 355 nm, and 364 nm. We also tried the extraction
with and without the addition of hydrochloric acid. Without
HCl the average drug recovery was 23% while the addition
of the acid increased recovery to an overall average of
92%.
During method development several organic solutions
and mixtures were tested including acetonitrile, methanol,
acetonitrile:methanol (1 : 1), hexane, ethyl acetate, methylene
chloride, and chloroform. With the exception of chloroform
the recoveries for the solutions used ranged from 68 to 80%.
There was also decreased peak resolution and/or interference
from plasma components compared to chloroform. Once
chloroform was selected as the extraction solvent the appro-
priate volume was determined. One milliliter produced a
recovery of roughly 75% for both meloxicam and piroxicam
and 3mL produced the same recovery as 2mL which was
the volume selected. We also looked at different methods for
mixing the samples and found that vortexing the samples for
sixty seconds produced a greater recovery than rocking for
twenty minutes.
3.2. Analytical Method Validation
3.2.1. Specificity. For specificity testing, untreated crane,
bearded dragon, or sow plasma was prepared in the same
manner as study samples and no endogenous plasma com-
ponents from any species interfered with the elution of the
compounds of interest. Five different blank plasma samples
from adult male and female bearded dragons or cranes were
used in the prevalidation process and a blank sample from
each animal was included in the analysis. Five different
blank plasma samples from adult sows were used in the
prevalidation process and a blank sample from each animal
was also analyzed. Meloxicam and piroxicam metabolites
are biologically inactive so no effort was made to analyze
these compounds in any species. Figure 2 illustrates chro-
matograms of a (a) blank bearded dragon sample, (b) a
250 ng/mL spiked plasma standard, (c) a plasma sample
from a bearded dragon after intramuscular administration of
0.4mg/kg meloxicam, (d) a blank sandhill crane sample, (e)
an 800 ng/mL spiked plasma standard, (f) a plasma sample
from a sandhill crane after oral administration of 0.5mg/kg
piroxicam, (g) a blank sow milk sample, (h) a 250 ng/mL
spiked milk standard, and (i) a milk sample from a sow after
intramuscular administration with 0.8mg/kg meloxicam.
The retention times in both bearded dragon and sandhill
crane plasma were 7.3 and 5.9 minutes for meloxicam and
piroxicam, respectively. The retention times in milk were 7.6
and 5.9 minutes.
For milk specificity testing, untreated sow milk was
prepared in the same manner as study samples and no
endogenous milk components interfered with the elution of
the compounds of interest. Five different blank milk samples
from adult sows were used in the prevalidation process and a
blank sample from each animal was also analyzed.
3.2.2. Linearity, Accuracy, and Precision. The plasma peak
ratio (area of meloxicam or piroxicam divided by the internal
standard area) was plotted and produced a linear curve for
the concentration range used (5–10,000 ng/mL) for each drug
with a correlation coefficient of 0.995 to 0.999. The mean
slope, intercept, and r2 values are reported inTables 1, 2, and 3.
Intra- and inter-day assay relative standard deviation (RSD)
for plasma spiked with specific concentrations of meloxicam
or piroxicam were used to determine accuracy and precision
which ranged from 1.1% to 11.3%. The precision was found to
be below the set ±15% for all quality control samples. The use
of an internal standard corrects for the intra- and interday
assay variability in the assay.
3.2.3. Recovery and Limit of Quantification (LLOQ). The
recovery (Tables 4, 5, and 6) of meloxicam and piroxicam
from spiked plasma and milk was determined by comparing
areas of extracted plasma or milk samples to those of directly
injected analytes without undergoing extraction at concen-
trations of 15, 750, 1250, 3000, and 7500 ng/mL. The average
plasma recovery ranged from 91% to 97% for meloxicam and
from 88% to 94% for piroxicam. The average recovery from
milk ranged from 88% to 95% for meloxicam. The lower
limit of quantification (LLOQ) was 5 ng/mL for both drugs
in both plasma and milk matrix, which represents a peak
approximately five times the baseline noise. The LLOQ is
more than adequate for use in pharmacokinetic studies. If a
lower LLOQ is needed sample size could be increased.
3.2.4. Stability. Testing of the short term stability of the
quality control standards for both milk and plasma indicated
there was less than a 1% loss of either drug after 24 hours
in the autosampler and a 1% loss of both drugs after 24
hours in the refrigerator at 4∘C.Therefore, if there was power
or equipment failure samples could be reanalyzed. Samples
in our studies were stored at −80∘C, thawed one time, and
analyzed; however, there was no loss of drug after 2 freeze-
thaw cycles. There was also no loss of drug after two weeks of
storage at−80∘Cwhich is oneweek longer than study samples
were stored for analysis.
3.3. Application of Method
3.3.1. Method Application. Figure 3 is a representative con-
centration-time profile from a meloxicam pharmacokinetic
study conducted in bearded dragons (Pogona vitticeps) after
receiving a 0.4mg/kg intramuscular dose of meloxicam.
The 𝑇max, 𝐶max, and half-life for this animal were 0.75 h,
3953 ng/mL, and 4.9 h, respectively. Figure 4 is a represen-
tative concentration-time profile from a piroxicam pharma-
cokinetic study conducted in sandhill cranes (Grus canaden-
sis) after receiving a 0.5mg/kg oral dose of piroxicam. The
𝑇max,𝐶max, and half-life for this animal were 1 h, 4840 ng/mL,
and 73 h, respectively.
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Figure 2: Chromatograms for meloxicam and piroxicam. (a) Blank bearded dragon plasma sample, (b) a 250 ng/mL spiked plasma standard,
(c) a plasma sample from a bearded dragon after intramuscular administration of 0.4mg/kg meloxicam, (d) a blank sandhill crane plasma
sample, (e) an 800 ng/mL spiked plasma standard, (f) a plasma sample from a sandhill crane after oral administration of 0.5mg/kg piroxicam,
(g) a blank sow milk sample, (h) a 250 ng/mL spiked milk standard, and (i) a milk sample from a sow dosed with 0.8mg/kg meloxicam.
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Table 1: Intra-assay accuracy, precision and assay linearity for meloxicam in plasma.
Intra-assay variability (𝑛 = 5)
Concentration added
(ng/mL)
Concentration measured
(ng/mL) bearded dragon
(Mean ± S.D.)
R.S.D. (%) Concentration measured(ng/mL) pig (Mean ± S.D.) R.S.D. (%)
15 15 ± 0.71 4.6 15 ± 0.21 1.4
750 708 ± 28 4.0 757 ± 69 9.1
1250 1156 ± 46 4.0 1149 ± 2.8 0.25
3000 2982 ± 155 5.1 2990 ± 160 5.3
7500 7528 ± 758 10.0 7300 ± 680 9.3
Assay linearity (𝑛 = 5)
Mean ± S.D. R.S.D. (%) Mean ± S.D. R.S.D. (%)
𝑌-Intercept 0.0037 ± 0.0004 11.3 0.0033 ± 0.0003 9.1
Slope 0.0020 ± 0.0002 12.3 0.0021 ± 0.0002 9.5
𝑟
2 0.995 ± 0.0028 0.28 0.994 ± 0.0038 0.38
S.D.: standard deviation; 𝑛: number of samples; RSD: relative standard deviation.
Table 2: Intra-assay accuracy, precision and assay linearity for piroxicam in plasma.
Intra-assay variability (𝑛 = 5)
Concentration added
(ng/mL)
Concentration measured
(ng/mL) (Mean ± S.D.) R.S.D. (%)
15 21 ± 0.41 2.0
750 774 ± 27 3.5
1250 1293 ± 44 3.4
3000 3006 ± 69 2.0
7500 7517 ± 399 5.0
Assay linearity (𝑛 = 5)
Mean ± S.D. R.S.D. (%)
𝑌-Intercept −0.0106 ± 0.0004 3.44
Slope 0.0012 ± 0.000018 1.51
𝑟
2 0.997 ± 0.003 0.28
S.D.: standard deviation; 𝑛: number of samples; RSD: relative standard deviation.
Table 3: Intra-assay accuracy, precision and assay linearity for meloxicam in milk.
Intra-assay variability (𝑛 = 5)
Concentration added
(ng/mL)
Concentration measured
(ng/mL) (Mean ± S.D.) R.S.D. (%)
15 15 ± 0.41 2.7
750 727 ± 27 3.7
1250 1149 ± 30 2.6
3000 3000 ± 69 2.3
7500 7450 ± 399 5.3
Assay linearity (𝑛 = 5)
Mean ± S.D. R.S.D. (%)
𝑌-Intercept −0.0079 ± 0.0004 5.06
Slope 0.0017 ± 0.000013 0.76
𝑟
2 0.999 ± 0.003 0.30
S.D.: standard deviation; 𝑛: number of samples; RSD: relative standard deviation.
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Table 4: Inter-assay variability and recovery for meloxicam in plasma and (𝑛 = 5).
Concentration added
(ng/mL)
Concentration measured
bearded dragon
(ng/mL) (Mean ± S.D.)
R.S.D. (%) Recovery (%) Concentration measured pig(ng/mL) (Mean ± S.D.) R.S.D. (%) Recovery (%)
15 14 ± 1 7.1 97 15 ± 0.4 3.0 99
750 743 ± 15 2.1 91 746 ± 12 1.5 98
1250 1220 ± 73 6.0 94 1227 ± 21 1.7 95
3000 3011 ± 128 4.3 95 2970 ± 32 1.1 95
7500 7467 ± 562 7.5 95 7466 ± 330 4.4 95
SD: standard deviation; 𝑛: number of days; RSD: relative standard deviation.
Table 5: Inter-assay variability and recovery for piroxicam in plasma and (𝑛 = 5).
Concentration added
(ng/mL)
Concentration measured
(ng/mL) (Mean ± S.D.) R.S.D. (%) Recovery (%)
15 22 ± 2 9.9 88
750 746 ± 56 7.4 94
1250 1255 ± 142 11.3 88
3000 2976 ± 147 4.9 89
7500 7500 ± 419 5.6 88
SD: standard deviation; 𝑛: number of days; RSD: relative standard deviation.
Table 6: Inter-assay variability and recovery for meloxicam in milk
(𝑛 = 5).
Concentration added
(ng/mL)
Concentration measured
(ng/mL) (Mean ± S.D.)
R.S.D.
(%)
Recovery
(%)
15 17 ± 2 10.8 94
750 730 ± 68 9.2 91
1250 1233 ± 78 6.3 90
3000 2976 ± 131 4.4 95
7500 7500 ± 330 4.4 88
SD: standard deviation; 𝑛: number of days; RSD: relative standard deviation.
4. Conclusion
In conclusion, this HPLC method quantifies meloxicam or
piroxicam from plasma by combining a liquid extraction
procedure with ultraviolet detection. This analytical proce-
dure was authenticated in terms of recovery, linearity, LLOQ,
precision, and accuracy. The limit of quantification and
recovery are more than adequate for use in pharmacokinetic
studies. The results of this study indicate that this HPLC
procedure is a reproducible method that provides consistent
quantification of meloxicam or piroxicam in plasma from
different species.
It is a simple method that eliminates the need for mass
spectrometry, column switching, and large volumes of
organic solvents. It allows numerous samples to be processed
by a single technician. This method has been used success-
fully to determine meloxicam and piroxicam concentrations
in plasma and milk samples at this institution. This method
utilizes a small sample size of 100𝜇L making it potentially
useful for small dogs, cats, or other small animals. It could
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Figure 3: Concentration time profile of meloxicam in bearded
dragon plasma after a 0.4mg/kg intramuscular dose.
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Figure 4: Concentration time profile of piroxicam in sandhill crane
plasma after a 0.5mg/kg oral dose.
be particularly useful to investigators when conducting phar-
macokinetic studies in small animals which require multiple
sampling from the same animal.
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